390 related articles for article (PubMed ID: 26767073)
1. Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Vennepureddy A; Thumallapally N; Motilal Nehru V; Atallah JP; Terjanian T
J Clin Med Res; 2016 Feb; 8(2):63-75. PubMed ID: 26767073
[TBL] [Abstract][Full Text] [Related]
2. The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
John L; Cowey CL
Dermatol Ther (Heidelb); 2015 Sep; 5(3):151-69. PubMed ID: 26387031
[TBL] [Abstract][Full Text] [Related]
3. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.
Hughes T; Klairmont M; Sharfman WH; Kaufman HL
Cancer Biol Ther; 2021 Dec; 22(10-12):513-526. PubMed ID: 26418961
[TBL] [Abstract][Full Text] [Related]
5. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced melanoma - A changing landscape.
Hepner A; Salgues A; Anjos CAD; Sahade M; Camargo VP; Garicochea B; Shoushtari AN; Postow MA; Fernandes GS; Munhoz RR
Rev Assoc Med Bras (1992); 2017 Sep; 63(9):814-823. PubMed ID: 29239458
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
10. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
[TBL] [Abstract][Full Text] [Related]
11. Successes and setbacks of early investigational drugs for melanoma.
Orloff M; Valsecchi ME; Sato T
Expert Opin Investig Drugs; 2015; 24(8):993-7. PubMed ID: 26068553
[TBL] [Abstract][Full Text] [Related]
12. Sequencing of New and Old Therapies for Metastatic Melanoma.
Ratterman M; Hallmeyer S; Richards J
Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
[TBL] [Abstract][Full Text] [Related]
13. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
15. BRAF in malignant melanoma progression and metastasis: potentials and challenges.
Alqathama A
Am J Cancer Res; 2020; 10(4):1103-1114. PubMed ID: 32368388
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
17. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
18. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy.
Niezgoda A; Niezgoda P; Czajkowski R
Biomed Res Int; 2015; 2015():851387. PubMed ID: 26171394
[TBL] [Abstract][Full Text] [Related]
19. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
